3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins

Circulation Research

Volumn 83, Issue 7, 1998, Pages 683-690

  Essig, Marie ^a,c   Nguyen, Geneviève ^b   Prié, Dominique ^a   Escoubet, Brigitte ^a   Sraer, Jean Daniel ^b   Friedlander, Gérard ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL TENON   (France)

^c INSERM   (France)

Author keywords

Atherosclerosis; Endothelium; Isoprenoid; Plasminogen activator; Rho protein

Indexed keywords

ACTIN; ALPHA HYDROXYFARNESYLPHOSPHONIC ACID; COMPACTIN; CYTOCHALASIN D; ENZYME; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; NOCODAZOLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN FARNESYLTRANSFERASE; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HUMAN CELL; MALE; MICROTUBULE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; RAT; UMBILICAL VEIN;

EID: 0032487342     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.7.683     Document Type: Article

References (49)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Ross Lorimer A, MacFarlane PW, Killop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wayne Warnica J, Arnold JAO, Wun CC, Davis BR, Braunwald E, for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
4. The Post Coronary Artery Bypass Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med. 1997;336:153-162.
5. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
6. Buchwald H, Campos CT, Boer JR, Nguyen PA, Williams SE. Disease-free interval after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the program on the surgical control of the hyperlipidemia (POSCH). J Am Coll Cardiol. 1995;23:351-357.
7. Tanaka K, Sueishi K. Biology of disease: the coagulation and fibrinolysis system and atherosclerosis. Lab Invest. 1993;69:5-18.
8. Vassali JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072.
9. Lowe GDO, Drummond MM, Third JLHC, Bremner WF, Forbes CD, Prentice CRM, Laurie TDV. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinemia. Thromb Haemost. 1980;42: 1503-1507.
10. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med. 1991; 229:309-316.
11. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res. 1990;57:155-162.
12. Hamsten A, Walldius G, Szaposi A, Blomback M, De Farie U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
13. Malyszko J, Urano T, Knöfler R, Takada Y, Takada A. Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotoninergic system and serum lipids in Japanese monkeys. Thromb Res. 1995;81:397-402.
14. Isaacsohn JL, Setaro JF, Nicholas C, Davey JA, Diotalevi LJ, Christianson DS, Liskov E, Stein EA, Black HR. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol. 1994;74: 735-737.
15. Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 1997;78:84-87.
16. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood. 1994;83:3427-3436.
17. Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cell tPA synthesis and release. Int J Hematol. 1994;59:233-255.
18. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1986;83:8776-8780.
19. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest. 1980; 66:1094-1100.
20. Huarte J, Belin D, Vassalli J. Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell. 1985;43:551-558.
21. Charreau B, Cassard A, Tesson L, Le Mauff B, Navenot JM, Blanchard D, Lublin D, Soulillou JP, Anegon I. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation. 1994;58:1222-1229.
22. Jaffe E, Nachman R, Becker C, Minich C. Culture of human endothelial cells derived from umbilical veins. J Clin Invest. 1973;52:2745-2756.
23. Loskutoff DJ, Schleef RR. Plasminogen activators and their inhibitors. Methods Enzymol. 1988;163:293-302.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
25. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Posttranslational modification of p21rho proteins. J Biol Chem. 1992;267:20033-20038.
26. Chardin P, Bocquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM. The mammalian G protein RhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in vero cells. EMBO J. 1989;8:1087-1092.
27. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesion and actin stress fibers in response to growth factor. Cell. 1992;70:389-399.
28. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 1996;31:348-371.
29. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988;62:367-374.
30. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33:667-672.
31. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest. 1994;24:766-772.
32. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91:83-87.
33. Larsson O, Barrios C, Latham C, Ruiz J, Zetterberg A, Zickert P, Wejde J. Abolition of mevinolin-induced growth inhibition in human fibroblasts following transformation by simian virus 40. Cancer Res. 1989;49: 5605-5610.
34. Larsson O. Effect of virus-transformation and growth factor stimulation on isoprene biosynthesis in human fibroblasts: a correlation to cell growth. Cancer Biochem Biophys. 1995;14:243-256.
35. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expression in human advanced atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995;15:1444-1455.
36. Steinbrecher UP, Parthasarathy S, Leake DS, Wiztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-3887.
37. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821-1829.
38. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A. 1989;8866:8323-8327.
39. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995;270:23007-23012.
40. Aktories K. Bacterial toxins that target Rho proteins. J Clin Invest. 1997;99:827-829.
41. Fenton RG, Kung HF, Longo DL, Smith MR. Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol. 1992; 117:347-356.
42. Bifulco M, Laezza C, Aloj SM, Garbi C. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol. 1993;155:340-348.
43. Iimura O, Vrtovsnik F, Terzi F, Friedlander G. HMG CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture. Kidney Int. 1997;52:962-972.
44. Snyder RW, Lenburg ME, Seebaum AT, Grabel LB. Disruption of the cytoskeleton-extracellular matrix linkage promotes the accumulation of plasminogen activators in F9 derived parietal endoderm. Differentiation. 1992;50:153-162.
45. Botteri FM, Ballmer-Hofer K, Rajput B, Nagamine Y. Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J Biol Chem. 1990;265: 13327-13334.
46. Lee JS, von der Ahe D, Kiefer B, Nagamine Y. Cytoskeletal reorganisation and TAP differently modify AP-1 to induce the urokinase-type plasminogen activator gene in LLC-PK1 cells. Nucleic Acids Res. 1995; 21:3365-3372.
47. Irigoyen JP, Besser D, Nagamine Y. Cytoskeleton reorganisation induces the urokinase-type plasminogen activator gene via the ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem. 1997; 272:1904-1909.
48. Thyberg J, Hedin U, Sjvlind M, Palmberg M, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966-990.
49. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery diseases and the acute coronary syndrome. N Engl J Med. 1992;326:242-250/310-318.